• Study of common CLL cancer morphisms in Iranian genome profiles and side effects of indigenous drugs in Iran
  • Majid Mesgar Tehrani,1,* Ghazaleh Amini,2 Mohammad Mahdi Eslami,3 Reza Mir lohi,4
    1. Member of the Core Committee of the National Genomics Hub, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    2. Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
    3. Member of the Bioinformatics Research Group, Nasim Research Institute, Tehran, Iran
    4. Member of the Bioinformatics Research Group, Nasim Research Institute, Tehran, Iran


  • Introduction: Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy influenced by genetic polymorphisms.
  • Methods: Data were obtained from the NCBI database and analyzed using the pharmacogenomic software MegaGen to identify polymorphisms and evaluate drug-related adverse effects.
  • Results: Three major variants—rs2032582 and rs1128503 in ABCB1, and rs2293152 in STAT3—were found to be highly cited and significant in the Iranian CLL genome profile. These polymorphisms showed strong associations with disease susceptibility and adverse drug reactions.
  • Conclusion: For CLL treatment in Iranian patients, genetic screening for rs2032582, rs1128503, and rs2293152 is recommended before therapy. Detecting these polymorphisms enables clinicians to prescribe safer drugs with fewer side effects, improving personalized treatment outcomes.
  • Keywords: CLL, ABCB1, STAT3, Pharmacogenomics, Personalized Medicine